Victoza® is the commercial brand name of Liraglutide Injection, developed by Novo Nordisk. It is a once-daily injectable GLP‑1 receptor agonist. It activates GLP‑1 receptors to inhibit glucagon release, delay gastric emptying and reduce appetite, lowering blood glucose in a…
Trulicity® is the commercial brand name of Dulaglutide Injection, developed by Eli Lilly and Company. It is a long-acting GLP‑1 receptor agonist administered once weekly subcutaneously. It activates GLP‑1 receptors to suppress glucagon secretion, slow gastric emptying, reduce food intake…
TENELIA® is the commercial brand name of Teneligliptin Hydrobromide Tablets, developed by Mitsubishi Tanabe Pharma Corporation. It is a long-acting oral DPP-4 inhibitor. It inhibits dipeptidyl peptidase 4 to prolong the activity of endogenous GLP-1 and GIP, regulating blood glucose…
Chuanbeiqing® is the domestic commercial brand name of Magnesium Sulfate, Sodium Sulfate and Potassium Sulfate Concentrate Oral Solution, developed by Jumpcan Pharmaceutical Group Co., Ltd. As an isotonic bowel cleanser, the compound sulfate salts create high osmotic pressure inside intestines,…
Lijingqing® is the domestic commercial brand name of Ursodeoxycholic Acid Oral Suspension, developed by CYNogen Bio. It is a hydrophilic natural bile acid preparation. It reduces the accumulation of toxic hydrophobic bile acids in hepatocytes, protects liver and bile duct…
Jiatailai® is the domestic commercial brand name of Sacituzumab Tirumotecan for Injection, a Trop-2 targeted antibody-drug conjugate (ADC) independently developed by Kelun-Biotech. It consists of a humanized anti-Trop-2 monoclonal antibody conjugated with topoisomerase I inhibitor tirumotecan via a cleavable linker.…
SPINRAZA® is the commercial brand name of Nusinersen Sodium Injection, an antisense oligonucleotide therapeutic agent. It modulates the splicing of SMN2 pre‑mRNA, increases the production of functional survival motor neuron (SMN) protein, and alleviates motor neuron degeneration caused by spinal…
URECE® is the commercial brand name of Dotinurad Tablets, a selective urate reabsorption inhibitor developed by Fuji Yakuhin. It specifically inhibits renal URAT1 transporter, reduces uric acid reabsorption in proximal renal tubules, increases urinary uric acid excretion and lowers serum…
EYLEA® is the commercial brand name of Aflibercept Intravitreal Solution, developed by Bayer. It is a recombinant fusion protein that binds to vascular endothelial growth factor (VEGF) and placental growth factor (PlGF), blocking their binding to corresponding receptors, inhibiting pathological…
ZEPZELCA® is the commercial brand name of Lurbinectedin for Injection, a synthetic marine-derived alkylating antitumor agent. It binds to the minor groove of tumor cell DNA, inhibits gene transcription and induces apoptosis of malignant cells, while also regulating the tumor…